← All trials
NCT05651347
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 29, 2019
- Primary completion
- Dec 30, 2025
- Completion date
- Jan 31, 2026
- First posted
- Dec 15, 2022
- Last posted
- Dec 15, 2022
- Enrollment
- 336
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Monash UniversityLead sponsor
- Cerebral Palsy AllianceCollaborator
- Monash UniversityReponsible party - principal investigator
- National Health and Medical Research Council, AustraliaCollaborator
- Monash UniversitySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.